Thus, although this eliminated HCAR2/GPR109A as a drug target for the treatment of dyslipidemia, HCAR2 agonists do inhibit lipolysis, which potentially could be beneficial in e.g. diabetes. Here, HCAR2 is linked to diabetes mellitus.